Atara Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-2.56 Insider Own1.70% Shs Outstand101.60M Perf Week1.94%
Market Cap356.16M Forward P/E- EPS next Y-2.46 Insider Trans-6.74% Shs Float93.69M Perf Month27.08%
Income-247.70M PEG- EPS next Q-0.78 Inst Own- Short Float11.25% Perf Quarter-7.60%
Sales71.80M P/S4.96 EPS this Y12.40% Inst Trans0.30% Short Ratio4.36 Perf Half Y-67.84%
Book/sh2.53 P/B1.87 EPS next Y20.10% ROA-56.60% Target Price21.90 Perf Year-62.11%
Cash/sh4.41 P/C1.08 EPS next 5Y- ROE-92.40% 52W Range2.83 - 20.04 Perf YTD-69.92%
Dividend- P/FCF- EPS past 5Y-5.70% ROI-121.70% 52W High-77.42% Beta1.11
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin- 52W Low59.89% ATR0.60
Employees434 Current Ratio5.30 Sales Q/Q105.90% Oper. Margin- RSI (14)49.35 Volatility12.64% 10.65%
OptionableYes Debt/Eq0.00 EPS Q/Q119.90% Profit Margin- Rel Volume0.50 Prev Close4.74
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume2.42M Price4.53
Recom2.60 SMA2015.54% SMA50-14.31% SMA200-56.48% Volume305,387 Change-4.54%
Jul-20-22Downgrade Citigroup Neutral → Sell $8 → $3
Jul-13-22Downgrade Stifel Buy → Hold $16 → $5
Jul-13-22Downgrade JP Morgan Overweight → Neutral $10
May-10-22Downgrade Citigroup Buy → Neutral $15 → $8
May-13-21Upgrade JP Morgan Neutral → Overweight $23 → $29
Dec-09-20Downgrade Citigroup Buy → Neutral $20 → $27
Dec-08-20Reiterated H.C. Wainwright Buy $28 → $31
Nov-10-20Reiterated H.C. Wainwright Buy $26 → $28
Jun-30-20Initiated Evercore ISI Outperform
Jun-15-20Initiated H.C. Wainwright Buy $25
Apr-23-20Upgrade Citigroup Neutral → Buy $14
Nov-08-19Downgrade JP Morgan Overweight → Neutral $43 → $22
Sep-27-19Downgrade Goldman Neutral → Sell $14 → $9
Sep-16-19Downgrade Jefferies Buy → Hold $32 → $15
Jun-04-19Upgrade Citigroup Sell → Neutral $23 → $24
May-30-19Initiated ROTH Capital Buy
May-23-19Initiated Stifel Buy
Jan-23-19Initiated Mizuho Buy
Apr-10-18Initiated JP Morgan Overweight $56
Mar-16-18Initiated Guggenheim Neutral
Aug-16-22 10:09AM  
Aug-15-22 09:55AM  
Aug-11-22 01:13PM  
Aug-09-22 03:01PM  
Aug-08-22 05:35PM  
Aug-04-22 04:01PM  
Aug-03-22 04:01PM  
Aug-02-22 09:35AM  
Aug-01-22 04:01PM  
Jul-29-22 04:28PM  
Jul-13-22 05:19PM  
Jul-12-22 04:30PM  
Jul-06-22 04:01PM  
Jul-01-22 07:57PM  
Jun-10-22 07:31AM  
Jun-04-22 09:00AM  
Jun-03-22 04:01PM  
May-23-22 02:19PM  
May-20-22 06:49AM  
May-19-22 04:01PM  
May-11-22 06:14AM  
May-08-22 08:13AM  
May-06-22 04:01PM  
May-05-22 05:25PM  
May-03-22 08:55AM  
Apr-29-22 04:01PM  
Apr-28-22 04:01PM  
Apr-27-22 09:25AM  
Apr-26-22 03:01PM  
Apr-22-22 04:01PM  
Apr-08-22 04:01PM  
Apr-05-22 04:01PM  
Apr-04-22 04:01PM  
Mar-15-22 04:01PM  
Mar-10-22 06:10AM  
Mar-04-22 04:01PM  
Mar-02-22 08:00AM  
Feb-28-22 05:55PM  
Feb-24-22 01:58PM  
Feb-23-22 12:57PM  
Feb-18-22 10:47AM  
Feb-17-22 04:01PM  
Feb-07-22 04:01PM  
Jan-29-22 07:47AM  
Jan-26-22 04:30PM  
Jan-24-22 11:13AM  
Jan-10-22 08:30AM  
Jan-07-22 04:01PM  
Jan-06-22 10:00AM  
Jan-05-22 04:01PM  
Dec-13-21 07:15PM  
Dec-09-21 08:00AM  
Dec-03-21 04:01PM  
Nov-30-21 08:30AM  
Nov-08-21 04:01PM  
Nov-05-21 04:01PM  
Nov-04-21 04:01PM  
Oct-28-21 04:01PM  
Oct-27-21 11:01AM  
Oct-25-21 06:15AM  
Oct-13-21 07:30AM  
Oct-04-21 07:30AM  
Oct-01-21 06:14PM  
Sep-29-21 03:30AM  
Sep-27-21 08:30AM  
Sep-20-21 11:50AM  
Sep-03-21 04:01PM  
Sep-02-21 08:30AM  
Aug-09-21 09:30PM  
Aug-02-21 06:00PM  
Jul-21-21 12:01PM  
Jul-02-21 04:01PM  
Jul-01-21 04:30PM  
Jun-18-21 01:12AM  
Jun-07-21 12:40PM  
Jun-04-21 04:01PM  
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Touchon PascalPresident and CEOAug 16Sale5.0414,80674,548457,287Aug 18 06:24 PM
Dupont JakobEVP, Head of R&DAug 16Sale5.034,12420,760158,882Aug 18 06:21 PM
Murugan AmarSVP, GC & SecretaryAug 16Sale5.033,43017,269131,198Aug 18 06:21 PM
Koppikar UtpalChief Financial OfficerAug 16Sale5.045,94029,908197,589Aug 18 06:20 PM
Touchon PascalPresident and CEOJun 27Sale7.2014,220102,384472,093Jun 29 04:48 PM
Koppikar UtpalChief Financial OfficerJun 08Sale5.635,85332,952203,529Jun 10 04:20 PM
Murugan AmarSVP, GC & SecretaryMay 17Sale5.323,22317,134133,735May 19 05:20 PM
Koppikar UtpalChief Financial OfficerMay 17Sale5.325,58229,675207,592May 19 05:16 PM
Dupont JakobEVP, Head of R&DMay 17Sale5.323,87320,597163,006May 19 05:08 PM
Touchon PascalPresident and CEOMay 17Sale5.3213,91373,962486,313May 19 05:04 PM
Dupont JakobEVP, Head of R&DMar 01Sale9.862,22121,890166,879Mar 03 07:02 PM
Koppikar UtpalChief Financial OfficerMar 01Sale9.863,76337,090213,174Mar 03 07:02 PM
Murugan AmarSVP, GC & SecretaryMar 01Sale9.862,57725,400136,958Mar 03 07:02 PM
Touchon PascalPresident and CEOMar 01Sale9.868,82887,009500,226Mar 03 07:02 PM
Dupont JakobEVP, Head of R&DFeb 10Option Exercise9.585,00047,90095,594Feb 14 05:42 PM
Dupont JakobEVP, Head of R&DFeb 10Sale16.005,00080,00090,594Feb 14 05:42 PM
Koppikar UtpalChief Financial OfficerFeb 07Sale14.462,49636,096155,702Feb 09 04:35 PM
Dupont JakobEVP, Head of R&DJan 03Option Exercise9.585,00047,90095,594Jan 05 04:47 PM
Dupont JakobEVP, Head of R&DJan 03Sale16.015,00080,05090,594Jan 05 04:47 PM
Dupont JakobEVP, Head of R&DDec 01Option Exercise9.585,00047,90095,594Dec 03 04:15 PM
Dupont JakobEVP, Head of R&DDec 01Sale17.945,00089,68890,594Dec 03 04:15 PM
Newell JoeChief Operations OfficerNov 16Sale17.123,33257,034113,097Nov 18 05:54 PM
Touchon PascalPresident and CEONov 16Sale17.128,402143,816328,489Nov 18 05:55 PM
Murugan AmarSVP, GC & SecretaryNov 16Sale17.122,12436,35687,540Nov 18 05:53 PM
Dupont JakobEVP, Head of R&DNov 16Sale17.122,19937,64090,594Nov 18 05:52 PM
Koppikar UtpalChief Financial OfficerNov 16Sale17.123,65562,562157,714Nov 18 05:53 PM
Newell JoeChief Operations OfficerNov 15Option Exercise12.153,50042,525123,429Nov 17 04:15 PM
Newell JoeChief Operations OfficerNov 15Sale17.717,000124,004116,429Nov 17 04:15 PM
Fust Matthew KDirectorNov 04Sale19.5013,354260,40331,500Nov 05 04:28 PM
Dupont JakobEVP, Head of R&DNov 02Option Exercise9.585,00047,90097,793Nov 04 04:10 PM
Dupont JakobEVP, Head of R&DNov 02Sale16.415,00082,05092,793Nov 04 04:10 PM
Newell JoeChief Operations OfficerSep 22Option Exercise12.1510,500127,575130,429Sep 24 05:35 PM
Newell JoeChief Operations OfficerSep 22Sale17.0010,500178,500119,929Sep 24 05:35 PM
Newell JoeChief Operations OfficerSep 15Sale15.613,11648,647119,929Sep 17 04:36 PM
Newell JoeChief Operations OfficerAug 30Sale15.003,50052,500123,045Aug 31 05:05 PM